KORU Medical is committed to sustainability, with many of our product offerings being reusable to help pharmaceutical partners meet their sustainability goals. By emphasizing reusable products, we aim to minimize environmental impact and contribute to a more sustainable healthcare industry.

 KORU Medical’s focus on generating clinical evidence to support the efficacy and safety of its products demonstrates a dedication to evidence-based practice and a commitment to transparency and accountability. By showcasing our research findings through peer reviewed published papers, posters and abstracts at key conferences, we seek to enhance our reputation as a trusted leader in the field of subcutaneous therapy.

KORU Medical’s aggressive approach to protecting its intellectual property through patents reflects our commitment to safeguarding our investments in innovation and maintaining a competitive advantage in the market. With over 70 global patents and ongoing patent applications, we are well-positioned to defend our innovations and capitalize on new opportunities as they arise.

KORU Medical’s experience in the healthcare industry showcases our dedication to innovation, patient-centered care, and sustainability. With a focus on continuous improvement and collaboration, KORU Medical is well-positioned to drive positive change and improve patient outcomes in the years to come.

Our strategic vision for 2026 reflects a commitment to excellence, innovation, and strategic growth, positioning the company for continued success and leadership in the global market for subcutaneous therapy.

Can you tell us about Immunodeficiency Diseases, and how does KORU Medical assists patients dealing with them?

KORU Medical currently services over 40,000 immunodeficient patients globally.⁷ This journey began in 2010 with the first FDA clearance of Hizentra^®, a subcutaneous immunoglobulin drug. Immunodeficiency Diseases encompass a group of rare genetic disorders characterized by defects in the immune system, resulting in a weakened ability to fight off infections and diseases caused by various pathogens.⁸

These disorders, which include Primary Immunodeficiency (PIDD), Secondary Immunodeficiency (SID), and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), pose significant health risks to affected individuals. PIDD and SID are immunodeficiency disorders, while CIDP is an autoimmune disorder affecting the peripheral nervous system. Individuals with these conditions typically require lifelong replacement therapy with immunoglobulin (Ig) to reduce the risk of infection and maintain their health.⁸

Both IVIg and SCIg are forms of immunoglobulin therapy used to treat various medical conditions, including primary immunodeficiency diseases (PIDD), autoimmune diseases, and certain neurological conditions. Here’s a comparison of the two treatment modalities:

Intravenous Immunoglobulin Therapy (IVIg) and Subcutaneous Immunoglobulin Therapy (SCIg)⁹:

IVIg involves the intravenous administration of immunoglobulins, which are purified antibodies derived from human plasma. Treatment typically takes place in a hospital or clinical setting and is administered by a trained medical professional, such as a nurse or physician. IVIg infusions can take several hours to complete, depending on the dose and patient’s tolerance. Patients receiving IVIg may experience side effects such as headache, fever, chills, nausea, and allergic reactions. Despite the inconvenience of hospital visits and potential side effects, IVIg therapy remains an effective treatment option for many patients with PIDD and other conditions.⁹

SCIg involves the subcutaneous administration of immunoglobulins, which are injected under the skin using a needle, syringe and an infusion pump. Unlike IVIg, SCIg therapy can be administered at home by the patients themselves or with the assistance of a caregiver, following appropriate training from healthcare professionals. SCIg infusions can be scheduled at times convenient for the patient, offering flexibility and independence in managing treatment. Because SCIg is absorbed slowly into the bloodstream, it can lead to more stable antibody levels over time compared to IVIg.¹⁰ Additionally, SCIg therapy is associated with a lower rate of adverse events and side effects compared to IVIg, making it a preferred option for some patients.¹¹ While SCIg therapy may require more frequent infusions compared to IVIg, the ability to administer treatment at home and reduce the need for hospital visits can lead to lower healthcare costs and improved quality of life for patients.⁹

KORU Medical plays a crucial role in assisting patients dealing with Immunodeficiency Diseases by offering simple, easy-to-use, and cost-effective home-based subcutaneous infusion treatments. Subcutaneous immunoglobulin (SCIg) drug therapy and our Freedom Infusion System allows patients to self-administer their medication in the comfort of their own home, providing them with greater control over their treatment schedule and environment.

By enabling home-based SCIg therapy, KORU Medical empowers patients with Immunodeficiency to take an active role in managing their condition, promoting a sense of independence and autonomy. Patients no longer need to rely solely on healthcare professionals or visit healthcare facilities for their infusion treatments, which can be especially beneficial for individuals with chronic conditions requiring lifelong therapy.

In addition to the convenience and flexibility afforded by home-based SCIg therapy, KORU Medical’s solutions are designed to be user-friendly, ensuring that patients can easily and safely administer their medication. This simplicity and accessibility are essential for promoting adherence to treatment regimens and improving patient outcomes.